These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23342271)

  • 1. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.
    Horio M; Kato T; Mii S; Enomoto A; Asai M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
    Cancer Med; 2012 Oct; 1(2):218-29. PubMed ID: 23342271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].
    Zhang W; Wu FX; Wang Q; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):286-91. PubMed ID: 22781116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
    Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
    Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
    Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
    BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
    Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
    Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance.
    Yang YI; Ahn JH; Lee KT; Shih IeM; Choi JH
    Cancer Res; 2014 Apr; 74(8):2258-69. PubMed ID: 24566868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer.
    Pan WW; Zhou JJ; Yu C; Xu Y; Guo LJ; Zhang HY; Zhou D; Song FZ; Fan HY
    J Biol Chem; 2013 Oct; 288(41):29680-91. PubMed ID: 23995842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
    Wang H; Zhu L; Gao J; Hu Z; Lin B
    Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
    Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R
    Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer.
    Yan X; Yin J; Yao H; Mao N; Yang Y; Pan L
    Cancer Res; 2010 Feb; 70(4):1616-24. PubMed ID: 20103635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.
    Luo Q; Wu X; Zhang Y; Shu T; Ding F; Chen H; Zhao P; Chang W; Zhu X; Liu Z
    Cancer Lett; 2018 Jul; 427():9-17. PubMed ID: 29660381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells.
    Niimi K; Murakumo Y; Watanabe N; Kato T; Mii S; Enomoto A; Asai M; Asai N; Yamamoto E; Kajiyama H; Shibata K; Kikkawa F; Takahashi M
    Cancer Sci; 2014 May; 105(5):545-52. PubMed ID: 24597627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
    Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
    Bradley A; Zheng H; Ziebarth A; Sakati W; Branham-O'Connor M; Blumer JB; Liu Y; Kistner-Griffin E; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Landen CN; Eblen ST
    Carcinogenesis; 2014 May; 35(5):1100-9. PubMed ID: 24379240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization.
    Wu YH; Chang TH; Huang YF; Chen CC; Chou CY
    Oncotarget; 2015 Sep; 6(27):23748-63. PubMed ID: 26087191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
    Chen L; Liang L; Yan X; Liu N; Gong L; Pan S; Lin F; Zhang Q; Zhao H; Zheng F
    Int J Gynecol Cancer; 2013 Feb; 23(2):256-63. PubMed ID: 23358177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.